Severe autoimmune hepatitis in a chronic myeloid leukemia patient treated with interferon alpha and with complete genetic response.
A patient with chronic myeloid leukemia (CML) treated with interferon alpha (IFN alpha) and who developed autoimmune hepatitis (AIH) is described. The patient was treated with IFN alpha 2a, a complete cytogenetic response was achieved 5 months later, and this response has lasted now more than 7 years. Autoimmune hypothyroidism appeared at 18 months of treatment, and 1 year later severe type I autoimmune hepatitis developed. To our knowledge this is the first report of such complication in an IFN alpha-treated CML patient.
Steegmann
J L
JL
Hematology Department, Hospital Universitario de la Princesa, Madrid, Spain.
Requena
M J
MJ
García-Buey
M L
ML
Granados
E
E
Romero
R
R
Fernández-Rañada
J M
JM
Moreno
R
R
D001327:Autoimmune Diseases / Q000209:etiology*; D015139:Blotting, Southern; D005260:Female; D006505:Hepatitis / Q000209:etiology* / Q000276:immunology*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use*; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000628:therapy*; D008875:Middle Aged; D012720:Severity of Illness Index
D016898:Interferon-alpha